These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 8821198)

  • 1. Pharmacokinetics of zidovudine in HIV-infected patients with end-stage renal disease.
    Kimmel PL; Lew SQ; Umana WO; Li PP; Gordon AM; Straw J
    Blood Purif; 1995; 13(6):340-6. PubMed ID: 8821198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of azidothymidine and its major metabolite glucuronylazidothymidine in hemophiliacs coinfected with human immunodeficiency virus and chronic hepatitis C.
    Rockstroh JK; Reichel C; Hille H; Oldenburg J; Brackmann HH
    Am J Ther; 1998 Nov; 5(6):387-91. PubMed ID: 10099082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmacokinetics of 3'-azido-3 deoxy-thymidine (AZT) in a patient undergoing hemodialysis].
    Deray G; Diquet B; Martinez F; Vidal AM; Petitclerc T; Land G; Raymond F; Baumelou A; Jacobs C
    Therapie; 1989; 44(6):405-8. PubMed ID: 2623654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacokinetics of zidovudine (AZT) and its metabolite (G-AZT) in healthy subjects and in patients with kidney failure].
    Pioger JC; Taburet AM; Colin JN; Colaneri S; Fillastre JP; Singlas E
    Therapie; 1989; 44(6):401-4. PubMed ID: 2623653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute liver failure enhances oral plasma exposure of zidovudine in rats by downregulation of hepatic UGT2B7 and intestinal P-gp.
    Wang F; Miao MX; Sun BB; Wang ZJ; Tang XG; Chen Y; Zhao KJ; Liu XD; Liu L
    Acta Pharmacol Sin; 2017 Nov; 38(11):1554-1565. PubMed ID: 28770824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zidovudine disposition in patients with severe renal impairment: influence of hemodialysis.
    Singlas E; Pioger JC; Taburet AM; Colin JN; Fillastre JP
    Clin Pharmacol Ther; 1989 Aug; 46(2):190-7. PubMed ID: 2758728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of acetaminophen on zidovudine metabolism in HIV-infected patients.
    Steffe EM; King JH; Inciardi JF; Flynn NF; Goldstein E; Tonjes TS; Benet LZ
    J Acquir Immune Defic Syndr (1988); 1990; 3(7):691-4. PubMed ID: 2352121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of hemodialysis on zidovudine (AZT) and its glucuronide (GAZT) pharmacokinetics: two case reports.
    Garraffo R; Cassuto-Viguier E; Barillon J; Chanalet L; Lapalus P; Duplay H
    Int J Clin Pharmacol Ther Toxicol; 1989 Nov; 27(11):535-9. PubMed ID: 2613387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of zidovudine in end-stage renal disease: influence of haemodialysis.
    Pachon J; Cisneros JM; Castillo JR; Garcia-Pesquera F; Cañas E; Viciana P
    AIDS; 1992 Aug; 6(8):827-30. PubMed ID: 1418779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolism and pharmacokinetics of the combination Zidovudine plus Lamivudine in the adult Erythrocebus patas monkey determined by liquid chromatography-tandem mass spectrometric analysis.
    Divi RL; Doerge DR; Twaddle NC; Shockley ME; St Claire MC; Harbaugh JW; Harbaugh SW; Poirier MC
    Toxicol Appl Pharmacol; 2008 Jan; 226(2):206-11. PubMed ID: 17949768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma levels of zidovudine twice daily compared with three times daily in six HIV-1-infected children.
    Bergshoeff AS; Fraaij PL; Verweij C; van Rossum AM; Verweel G; Hartwig NG; de Groot R; Burger DM
    J Antimicrob Chemother; 2004 Dec; 54(6):1152-4. PubMed ID: 15537694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A nonprimate animal model applicable to zidovudine pharmacokinetics in humans: inhibition of glucuronidation and renal excretion of zidovudine by probenecid in rats.
    Mays DC; Dixon KF; Balboa A; Pawluk LJ; Bauer MR; Nawoot S; Gerber N
    J Pharmacol Exp Ther; 1991 Dec; 259(3):1261-70. PubMed ID: 1762074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic evaluation of drug interactions with anti-human immunodeficiency virus drugs. VI. Effect of the calcium channel blocker nimodipine on zidovudine kinetics in monkeys.
    Gallo JM; Swagler AR; Mehta M; Qian M
    J Pharmacol Exp Ther; 1993 Jan; 264(1):315-20. PubMed ID: 8423534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zidovudine pharmacokinetics in five HIV seronegative patients undergoing continuous ambulatory peritoneal dialysis.
    Kremer D; Munar MY; Kohlhepp SJ; Swan SK; Stinnett EA; Gilbert DN; Young EW; Bennett WM
    Pharmacotherapy; 1992; 12(1):56-60. PubMed ID: 1549540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Steady-state pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with end-stage renal disease receiving chronic dialysis.
    Bohjanen PR; Johnson MD; Szczech LA; Wray DW; Petros WP; Miller CR; Hicks CB
    Antimicrob Agents Chemother; 2002 Aug; 46(8):2387-92. PubMed ID: 12121909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic evaluation of drug interactions with anti-human immunotrophic virus (HIV) Drugs. III. 2',3'-Dideoxycytidine (ddC) and zidovudine in monkeys.
    Qian MX; Swagler AR; Mehta M; Vishwanathan CT; Gallo JM
    Pharm Res; 1992 Feb; 9(2):224-7. PubMed ID: 1313173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of zidovudine in patients with liver cirrhosis.
    Taburet AM; Naveau S; Zorza G; Colin JN; Delfraissy JF; Chaput JC; Singlas E
    Clin Pharmacol Ther; 1990 Jun; 47(6):731-9. PubMed ID: 2357867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of standard breakfast on pharmacokinetics of oral zidovudine in patients with AIDS.
    Ruhnke M; Bauer FE; Seifert M; Trautmann M; Hille H; Koeppe P
    Antimicrob Agents Chemother; 1993 Oct; 37(10):2153-8. PubMed ID: 8257138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intensive pharmacokinetics of zidovudine 200 mg twice daily in HIV-1-infected patients weighing less than 60 kg on highly active antiretroviral therapy.
    Cressey TR; Leenasirimakul P; Jourdain G; Tawon Y; Sukrakanchana PO; Lallemant M
    J Acquir Immune Defic Syndr; 2006 Jul; 42(3):387-9. PubMed ID: 16810125
    [No Abstract]   [Full Text] [Related]  

  • 20. Plasma and cellular markers of 3'-azido-3'-dideoxythymidine (AZT) metabolism as indicators of DNA damage in cord blood mononuclear cells from infants receiving prepartum NRTIs.
    Meng Q; Olivero OA; Fasco MJ; Bellisario R; Kaminsky L; Pass KA; Wade NA; Abrams EJ; Nesel CJ; Ness RB; Bigbee WL; O'Neill JP; Walker DM; Poirier MC; Walker VE
    Environ Mol Mutagen; 2007; 48(3-4):307-21. PubMed ID: 17358024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.